0001104659-22-080577.txt : 20220718 0001104659-22-080577.hdr.sgml : 20220718 20220718173424 ACCESSION NUMBER: 0001104659-22-080577 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220714 FILED AS OF DATE: 20220718 DATE AS OF CHANGE: 20220718 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: PIERCE GLENN CENTRAL INDEX KEY: 0001256964 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37625 FILM NUMBER: 221089952 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Voyager Therapeutics, Inc. CENTRAL INDEX KEY: 0001640266 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 64 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 857-259-5340 MAIL ADDRESS: STREET 1: 64 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 4 1 tm2221315-2_4seq1.xml OWNERSHIP DOCUMENT X0306 4 2022-07-14 0 0001640266 Voyager Therapeutics, Inc. VYGR 0001256964 PIERCE GLENN C/O VOYAGER THERAPEUTICS, INC., 64 SIDNEY STREET CAMBRIDGE MA 02139 1 0 0 0 Common Stock 2022-07-14 4 S 0 9512 6.70 D 16788 D Common Stock 5000 I See Footnote Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on July 13, 2022. The reporting person structured the durable automatic sales instructions to constitute a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1. The sales do not represent a discretionary trade by the reporting person. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.70 to $6.74, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. The securities are directly held by the Pierce Family Trust, dated October 13, 1993 (the "Pierce Family Trust"). The reporting person's immediate family members are beneficiaries of the Pierce Family Trust. The reporting person expressly disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein. /s/ Robert Hesslein, as Attorney-in-Fact for Glenn Pierce 2022-07-18